Lexaria Bioscience Corp.
Lexaria Bioscience Corp. (LEXX): 8 pipeline candidates · ~7 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.4 months
D/E 0.04 · 0% dilution
Lead: Phase 1
8 candidates
N/A
N/A
A transparent, data-derived signal for Lexaria Bioscience Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$15.1M
Cash
$5.1M
Quarterly Burn
$2.2M
Runway
7.4 mo
Revenue
$20K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| arm 1 - dehydratech-cbd alone | Phase 1 |
| arm 2 - dehydratech-semaglutide alone | Phase 1 |
| arm 4 - rybelsus medication alone | Phase 1 |
| arm 5- tirzepatide | Phase 1 |
| dehydratech-cbd | Phase 1 |
| dehydratech-liraglutide | Preclinical |
| dehydratech-semaglutide | Phase 1 |
| dehydratech-tirzepatide | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
27
Total value held
$1.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 444,586 | $347K |
| invenomic capital management lp | 442,301 | $345K |
| geode capital management, llc | 294,157 | $229K |
| toronto dominion bank | 140,013 | $109K |
| vanguard fiduciary trust co | 94,166 | $73K |
| state street corp | 39,301 | $31K |
| blackrock, inc. | 27,445 | $21K |
| xtx topco ltd | 25,067 | $20K |
| krilogy financial llc | 19,653 | $19K |
| vontobel holding ltd. | 23,000 | $18K |
Showing top 10 of 27 institutional holders of Lexaria Bioscience Corp.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Lexaria Bioscience Corp.'s pipeline?
Lexaria Bioscience Corp. (LEXX) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Lexaria Bioscience Corp.'s lead drug candidate?
Lexaria Bioscience Corp.'s most advanced tracked candidate is arm 1 - dehydratech-cbd alone (Phase 1) for Type2diabetes.
What is Lexaria Bioscience Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Lexaria Bioscience Corp. has approximately 7.4 months of cash runway.
What is Lexaria Bioscience Corp.'s market capitalization?
Lexaria Bioscience Corp.'s market capitalization is approximately $15.1M.
Who is the CEO of Lexaria Bioscience Corp.?
Mr. Richard C. Christopher is the chief executive officer of Lexaria Bioscience Corp. (LEXX).
Get the full picture on Lexaria Bioscience Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.